[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Outpace Bio, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100644293","phase-1-a-phase-1-study-to-evaluate-the-safety-and-efficacy-of-opb-201-in-recurrent-endometrial-and-platinum-resistant-ovarian-cancer-100644293",false,"NCT07664735","A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.","A Phase 1a\u002Fb Study to Evaluate the Safety and Efficacy of OPB 201, an Autologous PReferentially Expressed Antigen of MElanoma (PRAME) T Cell Receptor (TCR) T Cell Therapy in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.","Inclusion Criteria:\n\n1. Age ≥ 18 years of age at the time of signing the informed consent form.\n2. Histologically confirmed diagnosis of endometrial cancer, epithelial ovarian, peritoneal, or fallopian tube cancer based on local histopathological findings.\n3. Received at least 1 prior line of systemic chemotherapy including a platinum-based chemotherapy.\n4. Received prior therapy with a PARP inhibitor if the subject has a known germline or somatic BRCA1\u002F2 mutation.\n5. Measurable disease.\n6. Consent to provide archived tumor tissue sample.\n7. ECOG performance status of 0 or 1.\n8. Adequate organ function.\n9. HLA-A \\*02:01 or HLA-A \\*02:02\n10. PRAME positive tumor\n\nExclusion Criteria:\n\n1. Women of child-bearing potential who are pregnant or breastfeeding.\n2. Uncontrolled bacterial, fungal, or viral infections.\n3. Active infection requiring systemic therapy.\n4. Bleeding or thrombotic disorders or at risk for severe hemorrhage.\n5. Any form of primary immunodeficiency.\n6. Had an allogenic tissue\u002Fsolid organ transplant.\n7. Active autoimmune disease.\n8. Concurrent treatment with systemic high dose corticosteroids.\n9. Unresolved acute effects of any prior therapy.\n10. Other exclusions as stated in the protocol.","FEMALE","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The goal of this clinical trial is to learn if OPB-201 is safe in recurrent endometrial and platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-201. Participants will have their own T cells modified in a laboratory and given back to them as OPB-201 in this one-time treatment. Participants will be in the hospital when they receive OPB-201 and then be checked at the clinical site frequently for the first few months.",[26,27,28,29,30,31,32],"Endometrial Cancer Recurrent","Endometrial Cancer","Advanced Endometrial Cancer","Ovarian Cancer","Ovarian Cancer Recurrent","Platinum Resistant Ovarian Cancer","Endometrial Cancers",[34,35,36,37,38,39,40,41,42],"Outpace","Ovarian cancer","Endometrial cancer","advanced ovarian cancer","advanced endometrial cancer","cell therapy","TCR-T","TCR","PRAME directed TCR","NOT_YET_RECRUITING","2026-06-17",{"date":46,"type":47},"2026-06-24","ACTUAL",{"date":49,"type":20},"2026-06-30",{"date":51,"type":20},"2030-09",{"name":53,"class":54},"Outpace Bio, Inc.","INDUSTRY",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":21,"phases":63,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100595319","phase-1-a-study-to-evaluate-the-safety-and-efficacy-of-opb-101-in-platinum-resistant-ovarian-cancer-100595319","NCT07030907","A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer","A Phase 1a\u002Fb Study to Evaluate the Safety and Efficacy of OPB-101, an Autologous Mesothelin (MSLN) CAR T Cell Therapy With Antigen-dependent Expression of OUTSMART™ Designed IL-2 Cytokine in Platinum-resistant Ovarian Cancer","Inclusion Criteria:\n\n1. Age ≥ 18 years of age at the time of signing the informed consent form.\n2. Histologically confirmed diagnosis of high grade serous epithelial ovarian, peritoneal, or fallopian tube cancer based on local histopathological findings.\n3. Recurrent platinum-resistant disease defined as: Disease that has recurred within 6 months of the last receipt of platinum-based therapy.\n4. Received at least 2 prior lines of systemic chemotherapy including a platinum-based chemotherapy.\n5. Received prior therapy with a PARP inhibitor if the subject has a known germline or somatic BRCA1\u002F2 mutation.\n6. Measurable disease.\n7. Consent to provide archived tumor tissue sample.\n8. ECOG performance status of 0 or 1.\n9. Adequate organ function.\n10. Alkaline phosphatase ≤ 2.5 x ULN\n11. ≤ Grade 1 dyspnea and oxygen saturation levels (SpO2) \\> 92% on room air.\n12. LVEF ≥ 50%\n13. Life expectancy of ≥ 3 months\n14. Adequate venous access.\n15. Negative screen for infectious disease markers.\n16. Negative serum pregnancy test.\n17. Abstain from heterosexual activity or to use 2 forms of effective methods of contraception.\n\nNote: Other protocol defined inclusion criteria could apply\n\nExclusion Criteria:\n\n1. Women of child-bearing potential who are pregnant or breastfeeding.\n2. Uncontrolled bacterial, fungal, or viral infections.\n3. Active infection requiring systemic therapy.\n4. Bleeding or thrombotic disorders or at risk for severe hemorrhage.\n5. Any form of primary immunodeficiency.\n6. Had an allogenic tissue\u002Fsolid organ transplant.\n7. Active autoimmune disease.\n8. Concurrent treatment with systemic high dose corticosteroids.\n9. Unresolved acute effects of any prior therapy.\n10. Active invasive cancer other than the cancer under study.\n11. Significant lung disease.\n12. Clinically significant pericardial effusion.\n13. Prior radiotherapy within 2 weeks of start of study intervention.\n14. No major surgery within 28 days prior to enrollment.\n15. Received investigational agents or tumor vaccines.\n16. Received chemotherapy within the previous 3 weeks.\n17. History of grade ≥ 3 ascites.\n18. Active CNS involvement.\n19. Received a live vaccine within 30 days prior to study treatment.\n20. Received prior CAR T cell therapy.\n21. Received prior mesothelin targeted therapy.\n22. Dependent on intravenous hydration or total parenteral nutrition. Note: Other protocol defined exclusion criteria could apply",{"count":19,"type":20},[23],"The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101.\n\nParticipants will have their own T cells modified in a laboratory and given back to them as OPB-101 in this one-time treatment. Participants will be in the hospital when they receive OPB-101 and then be checked at the clinical site frequently for the first few months.",[30,29,31],[34,35,67,39,68],"Advanced ovarian cancer","CAR T","RECRUITING","2025-12-11",{"date":72,"type":47},"2025-12-18",{"date":74,"type":47},"2025-06-16",{"date":76,"type":20},"2030-05-15",{"name":53,"class":54},4,""]